In recent years, immunophenotypic studies followed by functional validation have proposed a series of novel surface markers that, alone or in combination, might prove extremely useful to refine the identification and the enumeration of CML LSCs within the CD34+CD38− fraction, and in some cases, even enable their therapeutic targeting. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.